Welcome!

CareOregon Pharmacy









Heart Failure: Turn Down the Volume!



CareOregon Pharmacy







Today's Agenda

- Welcome and Introduction 8:00
- HFpEF vs HFrEF; Self-care 8:05
- Medication Review 8:55
- Break 9:30
- Disease Progression 9:45
- Advanced Illness Care 10:00
- Palliative Care 10:10
- Questions 10:45
- Closing 11:30





Learning Objectives

- 1. Describe the 2 types of heart failure.
- 2. Identify key drug classes to treat heart failure.
- 3. Summarize the difference between NYHA Class II and IV.
- 4. Identify goals of palliative care for heart failure patients.







Scope of the Problem – Nationally

- Heart failure is a disease of epidemic proportions.
 Approximately 5.7 million Americans are currently living with heart failure*. 50% have decreased left heart function**.
- Approximately 1 million hospitalized a year***
- Average rate for 30 day all cause readmission on Hospital Compare is 24.7%.
- 12 billion dollars spent per year on 30 day readmissions alone.

*AHA 2015 update **2013 ACCP/AHA Guidelines *** MedPAC 2008







CCO Metric

- PQI 08: Heart Failure Readmissions
 - (Prevention Quality Indicators)
- Rate of hospitalizations for heart failure (lower is better)
- Benchmark: 264.9 per 100,000 member years











Hospitalization and Heart Failure

















Jayne Mitchell, ANP-BC, CHFN OHSU Heart Failure Program







Introducing Ms. J

49 year old female who is living with family. Here today for shortness of breath. History as follows:

- Age 14 hypertension (no treatment)
- BP ranging 160-180 systolic for years
- 4 children and pregnancies, first 3 with no problems
- 4th pregnancy felt awful, tired short of breath
- Short of breath, dyspnea on exertion and pedal edema after delivery- managed for months this way- no medications
- 1994 worsened shortness of breath, couldn't keep up at home had orthopnea and severe shortness of breath went to ER
- In ER noted to have cardiomegaly and pulmonary edema
- Echocardiogram ejection fraction (EF) 20%





What Is Heart Failure?

- Clinical syndrome that develops in response to myocardial insult, resulting in decline in the function of the heart (heart doesn't pump well and without intervention will get worse.)
- Heart failure triggers a neurohormonal response. Many of the medications are aimed at stopping this response.





Causes of Heart Failure:

- Coronary Artery Disease
- Hypertension
- Valvular disease
- Genetic
 - i.e. Duchenne muscular dystrophy, hypertrophic cardiomyopathy
- Congenital
- Peripartum
- Infiltrative (i.e. amyloidosis, hemochromatosis)
- Infections and inflammatory processes (i.e. Chagas disease)
- Metabolic disorders
- Toxins (i.e. alcohol, chemo, radiation therapy, illicit drugs)
- Incessant arrhythmias







Types of Heart Failure

HFrEF – Heart failure <u>reduced</u> ejection fraction

HFpEF – Heart failure <u>preserved</u> ejection fraction.

PRESERVED






What Type of Heart Failure Does Your Patient Have?

Look at echocardiogram

- EF equals amount of blood heart is pumping out of ventricle with each contraction.
- Hint... look for "diastolic dysfunction" or "systolic dysfunction"
- …look for valve or structural problems.

Ejection Fraction








Hospitalized HFpEF Prevalence Increasing

GWTG-HF: N=110,621 patients hospitalized with HF P<0.0001 for trend of increased HFpEF prevalence



Oktay AA, Rich JD, Shah SJ. *Curr Heart Fail Rep* 2013 Based on Steinberg et al. *Circulation* 2012






A Fundamental Issue: Are These Patients the Same or Different?


60 yo man with long history of HF 2 weeks of gradually worsening conditions BP 85/40

80 yo woman with long history of HTN 1 hour of sudden onset of symptoms BP 185/120


















How Similar Are These 2 Patients?


60 yo man with long history of HF 2 weeks of gradually worsening conditions BP 85/40

80 yo woman with long history of HTN 1 hour of sudden onset of symptoms BP 185/120
























HF Survival: Poor Regardless of EF



Dismal 35% survival at 5 years after HF hospitalization, regardless of LVEF


Owan T et al. N Engl J Med 2006; 355: 251-259





Hospitalizations = Poor Prognosis


All Cause Mortality After Each Subsequent Hospitalization For HF







Physical Exam – Both Types








Symptoms – Both Types

- Shortness of Breath (SOB) at <u>rest</u>
- Dyspnea On <u>Exertion</u> (DOE)
- Orthopnea
- Paroxysmal <u>Nocturnal</u> Dyspnea (PND)
- Abdominal bloating
- Edema









Stages & Treatment of HF

At Risk for Heart Failure

Structural heart

disease

STAGE A

At high risk for HF but without structural heart disease or symptoms of HF

e.g., Patients with:

Atherosclerotic disease

Metabolic syndrome

Using cardiotoxins

cardiomyopathy

· With family history of

THERAPY

· Heart healthy lifestyle

Prevent vascular.

coronary disease

abnormalities

· ACEI or ARB in

appropriate patients for

vascular disease or DM

Statins as appropriate

Prevent LV structural

• HTN

DM

Obesity

Patients

Goals

Drugs

STAGE B

Structural heart disease but without signs or symptoms of HF

e.g., Patients with:

Previous MI

including

LV remodeling

Asymptomatic

THERAPY

· Prevent HF symptoms

Prevent further cardiac

remodelina

ACEI or ARB as

Beta blockers as

In selected patients

Revascularization or

valvular surgery as

appropriate

appropriate

appropriate

Goals

Drugs

• ICD

LVH and low EF

valvular disease

Heart Failure

STAGE C

Structural heart disease with prior or current symptoms of HF

STAGE D Refractory HF

e.g. Patients with:

- · Known structural heart disease and
- HF signs and symptoms

Refractory symptom of HF at rest, despite GDMT

e.g patients with:

- Marked HF symptoms at
- Recurrent hospitalizations despite GDMT



THERAPY

Goals

Development of

symptoms of HF

- Control symptoms
- Improve HRQQL
- Prevent hospitalization
- Prevent mortality

Strategies

 Identification of comorbidities

Treatment

- Diuresis to relieve symptoms fo congestion
- Follow guideline driven indications for comorbidities, e.g. HTN, AF, CAD, DM
- Revascularization or vavular surgery as appropriate

Goals

- Control symptoms
- Patient education
- Prevent hospitalization

품

THERAPY

Prevent mortality

Drugs for routine use

- Diuresis for fluid retention
- ACEI or ARB, ARNI
- Beta Blockers
- Adiosterone antagonists

Drugs for use in selected patients

- Hydralazine/isosorbide
- ACEI and ARB
- Digoxin
- Ivabradine

In selected patients

- CRT
- ICD
- Revascularization or valvular as appropriate

THERAPY

Goals Control symptoms

- Improve HRQOL
- Prevent hospital readmissions
- Establish patient's endof-life-goals.

Options

- Advanced care measures
- Heart transplant
- Chronic inotropes Temporary or
- permanent MCS
- Experimental surgery of drugs
- Palliative care and hospice
- ICD deactivation









"HEFF - REFF"

Heart failure reduced ejection fraction (HFrEF)

- Left ventricular systolic dysfunction (LVSD)
- Ejection fraction (EF) less than 40%
- Decreased stroke volume
- Decreased CO
- Backward failure
- Forward failure

"HEFF - PEFF"

Heart failure preserved ejection fraction (HFpEF)
In general HFpEF occurs in older women with a history of hypertension, Obesity, CAD, A-fib and DM also common comorbidities







"HEFF - REFF"

Guideline Directed Medical Therapy includes:

- Diuretics to combat fluid retention
- ACEI or ARB (hydralazine and nitrates if cannot tolerate)
- Approved Beta Blockers
- Aldosterone antagonists

Selected pts

- Hydralazine and isosorbide dinitrate
- Digoxin

Selected pts

- ICD placement
- CRT
- Revascularization oF valvular surgery as appropriate

"HEFF - PEFF"

Strategies

Identify and treat comorbidities

Treatment

- Diuresis to relieve symptoms of congestion
- Follow guideline directed indications for comorbidities

(i.e. treat sleep apnea, hypertension, diabetes, etc.)

 Revascularization or valvular surgery as appropriate







Stages of Heart Failure and Treatment

STAGE C Structural heart disease STAGE D Refractory HF with prior or current symptoms of HF e.g patients with: Marked HF symptoms at e.g. Patients with: Refractory symptoms Known structural heart disease and of HF at rest, despite GDMT HF signs and symptoms Recurrent hospitalizations despite GDMT THERAPY THERAPY THERAPY Goals Goals Goals Control symptoms Control symptoms Control symptoms Patient education Improve HRQOL Improve HRQOL Prevent hospitalization Prevent hospitalization Prevent hospital Prevent mortality Prevent mortality readmissions Establish patient's end-Drugs for routine use Strategies of-life-goals. Diuresis for fluid retention Identification of ACEI or ARB, ARNI comorbidities Options Beta Blockers Advanced care measures. Adiosterone antagonists Treatment Heart transplant Diuresis to relieve Chronic inotropes Drugs for use in selected symptoms fo congestion Temporary or patients Follow guideline driven permanent MCS Hydralazine/isosorbide indications for Experimental surgery of comorbidities, e.g. HTN, ACEI and ARB drugs Digoxin AF, CAD, DM Palliative care and Ivabradine Revascularization or hospice vavular surgery as ICD deactivation In selected patients appropriate CRT ICD Revascularization or valvular as appropriate







Classification of Heart Failure

ACCF/AHA Stages of HF		NYHA Functional Classification	
A	At high risk for HF but without structural	None	
	heart disease or symptoms of HF.		
В	Structural heart disease but without signs	I	No limitation of physical activity.
	or symptoms of HF.		Ordinary physical activity does not cause
			symptoms of HF.
C	Structural heart disease with prior or	I	No limitation of physical activity.
	current symptoms of HF.		Ordinary physical activity does not cause
			symptoms of HF.
		II	Slight limitation of physical activity.
			Comfortable at rest, but ordinary physical
			activity results in symptoms of HF.
		III	Marked limitation of physical activity.
			Comfortable at rest, but less than ordinary
			activity causes symptoms of HF.
		IV	Unable to carry on any physical activity
D	Refractory HF requiring specialized		without symptoms of HF, or symptoms of
	interventions.		HF at rest.

Yancy, CW et al. 2013 ACCF/AHA Heart Failure Guideline





Ms. J

 What is likely to be the cause or etiology of her heart failure?

Etiology likely to be hypertensive or familial cardiomyopathy

What type of heart failure does she have?

HFrEF (echo with EF less than 40%)

What is the stage of heart failure she is in?

She is Stage C (structural changes and symptoms)

 She comes to office short of breath at rest before you send her to the emergency room, what NYHA class is she?

NYHA class IV (short of breath at rest)







Disease Trajectory – 50% Will be Dead in 5 Years




Figure 1.

Schematic Depiction of Comprehensive Heart Failure Care Figure illustration by Rob Flewell.







Disease Trajectory – 50% Will be Dead in 5 Years




Figure 1.

Schematic Depiction of Comprehensive Heart Failure Care Figure illustration by Rob Flewell.







Disease Trajectory – 50% Will be Dead in 5 Years




Figure 1.

Schematic Depiction of Comprehensive Heart Failure Care Figure illustration by Rob Flewell.





What are Goals of Therapy?

- Control symptoms
- Improve quality of life
- Prevent rehospitalization and mortality







How Are Goals of Therapy Addressed?

- Medications to stop neurohormonal process
- Patient should be euvolemic (not have extra fluid)
- Diet (salt=fluid)

Remember ...HF brings WOES

- Weights
- Observation
- Education of patient and family
- Symptom recognition and reporting







Compensatory Mechanisms

Neurohormonal activation

- Sympathetic nervous system
 - Vasoconstriction
 - Inotropism (increased contractility)
- Chronic SNS leads to increased myocardial O2 demand
 - Activation of Renin Angiotensin-Aldosterone system (RAAS)
 - Natriuretic peptide system
 - Vasopressin
 - o Endothelin

Dysregulation of immune system

Immune activation of pro-inflammatory cytokines







Left Ventricular Remodeling Post MI

1 week



EDV 137ml ESV 80ml EF 41%

3 months



EDV 189ml ESV 146ml EF 23%

Apical 4 Chamber View End-diastole



Sutton M, Sharpe N. Circulation 2000;101:2981-2988

Copyright © American Heart Association, Inc. All rights reserved.





Factors That Affect Cardiac Performance Impaired Renal Function

Ischemic insult

Cardiac surgery


Main determinant of renal function is renal blood flow

 Reduction in CO results in disproportionate reduction in renal perfusion

Leads to decreased GFR & Increased Cr.

Leads to neurohormonal activation


Worsening renal function change in serum cr >0.3 mg/dl or >25% over baseline








Factors That Affect Cardiac Performance Activation of Sympathetic Nervous System






- Fight or flight mechanism
- Elevates heart rate
- Heart works harder
- Leads to cell death





Factors That Affect Cardiac Performance Diuretic Resistance

- Persistent congestion despite diuretic therapy
- Distal tubules develop hypertrophy
- Oral absorption of loop diuretics is impaired in the setting of gut hypoperfusion and edema








Factors That Affect Cardiac Performance Hyponatremia

- Defined as serum sodium concentration less than 136 mmol/L
- Mild hyponatremia seen in approx 25 % of pts with HF
- Poses significantly greater risk of death post hospitalization
- As CO decreases
 vasopressin release from
 pituitary is stimulated
 leading to water retention
- High dose diuretics and increased water can exacerbate








Self-Care

The process of making decisions about symptoms when they are recognized





Nursing Goal – Teach Patient/Family To Be Experts




Source: Nat Rev Cardiovasc Med © 2011 Nature Publishing Group





Why Focus On Self-Care?

Better self care results in improved outcomes: reduced health care cost, length of stay for HF by as much as a 39-56%










Why Keep It Basic?









Why Does It Matter?

Early recognition of weight change and/or HF symptoms

- improves outcomes
- reduces re-hospitalizations
- improves patients' quality of life
 & functional status.







When To Notify Provider?

Symptoms

- SOB
- DOE

Weight Changes

± 3 lbs or more in one day

± 5 lbs or more in one week

- Orthopnea (using more pillows)
- PND (waking up in the middle of the night and can't breathe)
- Dizziness or lightheadedness with rapid rising
- Abdominal distention and bloating
- Edema





Teaching Fundamentals

- Daily weights have patients record also to encourage self-care
- Symptom recognition and reporting help patients recognize when symptoms arise or worsen and teach them when to consult their providers
- Low sodium diet so we don't have to use as much of the water pill (Water pills are hard on kidneys)
- Medications goal is good system in order to take meds. Basic understanding of meds.
- Activity encourage!





What About Fluid Restriction?

- Stage D per guidelines
- With hyponatremia
- Selected cases









Heart Failure Management Zones

GREEN ZONE:

You are in the green zone if you have:

- · No shortness of breath
- No swelling
- No weight gain
- No chest pain
- No decrease in your ability to maintain your activity level

Action:

- Continue taking your medication as ordered
- · Continue daily weights
- · Follow low salt diet
- · Keep all provider appointments

Help yourself feel better and stay out of the hospital by assessing what zone you are in: Green, Yellow or Red.

EVERY DAY:

- Weigh yourself the morning before breakfast and write it down
- Take your medicine
- Check for swelling in your feet, ankles, legs and stomach
- · Eat low-salt food
- Balance activity and rest periods
- Determine which zone you are in: Green, Yellow or Red

KNIGHT
CARDIOVASCULAR
INSTITUTE
Oregon Health & Science University

YELLOW ZONE:

You are in the yellow zone if you have:

- Weight gain of 3 or more pounds in 3 days
- Increased cough
- Increased swelling
- Increase in shortness of breath with activity
- Increase in number of pillows needed
- Anything else unusual that bothers you

Action:

- Call your provider if you are going into the yellow zone; you may need an adjustment of your medications.
- Contact information for physician, nurse coordinator or home health nurse:

NAME:	
NUMBER:	
NSTRUCTIONS:	
NSTRUCTIONS.	_

RED ZONE:

You are in the red zone if you have:

- Unrelieved shortness of breath: shortness of breath at rest
- Unrelieved chest pain
- Wheezing or chest tightness at rest
- · Need to sit in chair to sleep
- Weight gain or weight loss of more than 5 pounds in 2 days
- Confusion

Action:

- Call your provider IMMEDIATELY; you need to be evaluated by a provider right away.
- Contact information for provider:

NAME:		
NUMBER:		







Daily Weight & Zones Calendar

· Record your weight on this calendar every morning after you urinate and before you have breakfast.

MONTH: April 2017 • Place a check in the box that represents the color of your zone that day.


SUNDAY	MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SATURDAY
		162.6	160.2	160.8		
		V	√ □ □	V		
		164.0	163.4	164.0	164.2	164.2
V	1	V	1	1	1	1
167.2	166.8	166.2	164.8	166.0		
1		√ □ □	V	1		







Keep it Simple



- Weights
- Observation
- Education
- Symptoms





Ms. J Comes To My Office

- After hospital discharge...
- She lost 20 pounds in the hospital.
 Feeling much better.

 What can I do to help... Stage C, NYHA class III now?







Ms. J Comes To My Office

Goals of therapy

- Control symptoms
 - Teach patient to report symptoms
- Patient education
 - Optimize self care and encourage consulting behaviors
- Prevent hospitalization
 - Self care and optimize meds
- Prevent mortality
 - Optimize meds (can I up titrate anything?)






Please hold questions – thanks!













Medication Management

Pamela Chukwuleta, PharmD
Pharmacy Resident
CareOregon







My Easy

Name:	Mark Gra	ace
Date: _		
Primary	Doctor:	Dr. Harry Carry
-	ergies?	

Which medications matter most to you?

Drug name	Why I take this	How	do I feel ab	out it?	N
Lisinopril	Heart Failure	0 🙂	(o <u>=</u>	0 😕	
Losartan	Heart Failure	0 🙂	(O <u>u</u>	0 🙁	
Ibuprofen	Back Pain	0 🙂	0 =	0 😸	
		0 🙂	0 😐	08	
		00	0 😐	0 🙁	





Take Home Points

- What medications should the patient be taking?
- What medications should be avoided?
- Tools to address patient questions








Treatment Goals

- Prolong life
- Slow disease progression
- Prevent hospitalizations
- Reduce symptoms

Meds target "from different angles"







Medication Regimen

Prolong life

Reduce symptoms

- ACE or ARB or ARNI
- Beta Blocker
- Aldosterone Antagonist
- Hydralazine/nitrates
- Titrate to target doses

- Diuretics
- Digoxin
- Ivabradine
- Dose based on symptoms
- Less evidence on morbidity/mortality





Medications: HFrEF vs HFpEF

HFrEF

Guideline Directed Medical Therapy:

- ACE or ARB or ARNI
- Beta Blocker
- Aldosterone Antagonist
- Hydralazine/Nitrates
- Diuretic

HFpEF

- Treat co-morbidities
 - HTN, DM, Sleep apnea
 - ACE, ARB, and/or beta blocker in HTN
- Diuretic


All Patients: Self-Care & Smoking Cessation







ACEs & ARBs: How They Help









ACE Inhibitors: The "Prils"

- Benefits vs placebo
 - Improve survival by 20-30%
 - Fewer hospitalizations
 - Improve symptoms
 - Improve quality of life
- May reduce dose
 - Patient still receives valuable benefits

Generic	Brand
Captopril	Capoten
Enalapril	Vasotec
Fosinopril	Monopril
Lisinopril	Prinivil, Zestril
Perindopril	Aceon
Quinapril	Accupril
Ramipril	Altace
Trandolapril	Mavik







ACE Inhibitors Cont.

- Side Effects: dry cough, dizziness, hyperkalemia, angioedema
- Contraindications: history of angioedema, pregnancy, bilateral renal stenosis

Monitoring: serum creatinine, potassium

- Serum creatinine "bump" after starting
- May resolve within 1-2 weeks
- Potassium increase
- When to worry:
 - Serum creatinine > 2.5 or
 > +25% change from baseline
 - Potassium > 5







ARBs: The "Sartans"

- Less studies than ACEs
- Similar benefits: reduced morbidity/mortality
- Alternative when intolerant to ACEs
- ACE + ARB = more side effects, no benefit

Generic	Brand
Candesartan	Atacand
Valsartan	Diovan
Losartan	Cozaar





ARBs Cont.

- Side Effects: dizziness, headache, diarrhea, hyperkalemia
- Contraindications: pregnancy, bilateral renal stenosis


Monitoring: serum creatinine, potassium







Beta Blockers: How They Help









Beta Blockers: The "Olols"

Benefits

- Decreased mortality- 35-65%
- Fewer hospitalizations
- Reverse remodeling
- Improve symptoms & quality of life

Generic	Brand
Bisoprolol	Zebeta
Carvedilol	Coreg
Carvedilol CR	Coreg CR
Metoprolol succinate	Toprol XL





Beta Blockers Cont.

- Side Effects: fluid retention, dizziness, fatigue, hypotension
- Contraindications: decompensated HF, heart block, severe reactive airway disease

Monitoring: heart rate (<60 and symptomatic), blood pressure





Start Low & Go Slow


- May initiate simultaneously with ACEs
- Titrate <u>first</u> in stable patients
 - Greater benefit at target doses
- May worsen symptoms when started, gain weight
 - May happen with every dose increase
 - Resolve in 1-2 months
- Start low and go slow
- Don't stop suddenly → Rebound effect
- Hypotension? Take beta blocker & ACE at different times of day







Aldosterone Antagonsists: How They Help









Aldosterone Antagonists

- RALES trial
 - 30% reduction in all cause mortality
 - Reduced risk of sudden cardiac death & hospitalizations
- Appropriate patients
 - In addition to ACE/ARB + Beta Blocker
 - Serum creatinine < 2.5mg/dL; eGFR > 30ml/min
 - Potassium < 5 mEq/L</p>

Generic	Brand
Spironolactone	Aldactone
Eplerenone	Inspra





Aldosterone Antagonists Cont.

- Side Effects: gynecomastia (with spironolactone), hyperkalemia, fatigue, headache
- Contraindications: hyperkalemia, acute renal insufficiency

Monitoring: serum creatinine, potassium


- Reduce dose if potassium > 5.5 mEq/L
- Consider holding if patient has vomiting/diarrhea/dehydration







Vasodilators: How They Help









Hydralazine + Isosorbide Dinitrate

- Significant benefit in African American patients
 - In combo with ACE/ARB + BB + Aldosterone
 Antagonist
 - 43% decrease in mortality risk
- High pill burden: 3-6 pills per day
 - Combo Bidil cost-prohibitive

Generic	Brand
Hydralazine	Apresoline
Isosorbide Dinitrate	Isordil
Hydralazine + isosorbide dinitrate combo	Bidil





Vasodilators Cont.


- Side Effects: headache, dizziness, GI upset
- Contraindications: concurrent use with erectile dysfunction medications

Monitoring: blood pressure, CBC/Antinuclear antibody (if symptoms of lupus)





Diuretics: How They Help







Diuretics

- Benefits: control fluid retention, improve symptoms, reduce hospitalizations
 - Unclear mortality benefit
 - Loop diuretics preferred → better fluid reduction

Loop Diuretics		
Bumetanide	Bumex	
Furosemide	Lasix	
Torsemide	Demadex	

Thiazide-like Diuretic

Metolazone Zaroxolyn





Diuretics

- Take before 4pm to prevent nocturia
- Threshold and ceiling doses
- Furosemide: inter- and intrapatient variability
- Metolazone: longer half-life → electrolyte imbalances
- Side Effects: dizziness, leg cramps, photosensitivity, hypotension

Monitoring: daily weights, serum creatinine, blood urea nitrogen (BUN), potassium, magnesium







Diuretic Resistance

- Mechanisms:
 - Reduced renal perfusion
 - Increased levels of sodium-retaining hormones (angiotensin II and aldosterone)
 - Low albumin → slower delivery of drug to kidney
- Treatment approach
 - Switch to torsemide or bumetanide
 - IV diuretics
 - Add metolazone (take 30 mins before loop diuretics)







Shared Decision-Making in Diuretic Dosing


- Patients' experiences with diuretics
 - Doesn't take on Sundays when going to church
 - Doesn't take when out running errands
 - Doesn't take when going to the doctor
 - Homeless patients → limited access to restrooms
- Individualize the plan for each patient







Digoxin – How it Helps









Digoxin

- Not a first line agent
 - For symptomatic patients on target doses of GDMT
- Benefits: improve symptoms, quality of life
 - DIG trial: no difference in mortality vs placebo, reduced hospitalizations by 28%
- Don't stop digoxin if patient is already taking it
- Side Effects: confusion,
 GI upset, yellow vision
- Contraindications: heart block









New Drugs

Ivabradine (Corlanor)

FDA approved April 2015

Sacubitril & Valsartan (Entresto)

FDA approved July 2015

Valsartan: ARB


New drug class 'ARNI'







Angiotensin Receptor Neprilysin Inhibitor (ARNI): How it works









Sacubitril & Valsartan (Entresto)

- PARADIGM-HF trial
 - 16% additional reduction in all cause mortality compared to ACEI
 - Reduced risk of cardiovascular death & hospitalizations
- Appropriate patients
 - In place of ACE/ARB, in ACE/ARB tolerant patients

Generic	Brand	
Sacubitril & Valsartan	Entresto	





Sacubitril & Valsartan (Entresto)

- Meant to replace ACEI/ARB
- Washout period = 36 hours (Angioedema risk)
- Titrate to target dose over 2-4 weeks as tolerated
- Side Effects: hyperkalemia, hypotension, and renal dysfunction
- Contraindications: pregnancy


Monitoring: serum creatinine, blood pressure, potassium







Ivabradine: How it works









Ivabradine

SHIFT trial

Reduced risk of HF hospitalizations by 18% compared to placebo

Appropriate patients

- Patient on maximum tolerable doses of GDMT (especially beta blockers)
- Stable, symptomatic and persistently elevated HR ≥ 70 bpm

Generic	Brand
Ivabradine	Corlanor







Ivabradine

- Target HR 50 to 60 bpm
- CYP3A4 inhibitors: diltiazem, verapamil, grapefruit juice; inducers: rifampin, phenytoin
- Side Effects: low heart rate, atrial fibrillation, increased phosphenes (visual brightness)
- Contraindications: severe hypotension, pacemaker dependent, severe liver impairment

Monitoring: blood pressure, heart rate







HFpEF

- Treat co-morbidities
 - ACEs, ARBs, beta blockers for hypertension
- Diuretics
 - Low doses
 - Monitor for hypotension
 - Long term treatment with low-mod doses
 - Furosemide 20-40mg daily







Medications To Avoid In HF

- NSAIDs → reduce diuretic effectiveness by blocking prostaglandin-mediated increase in renal blood flow
- Calcium channel blockers: nifedipine, nicardipine, isradipine, diltiazem, verapamil
 - Amlodipine is ok
- Thiazolidinediones (TZDs): pioglitazone, rosiglitazone
- Antiarrhythmia meds: i.e. quinidine, procainamide
 - Amiodarone or Dofetilide are ok
- Erectile dysfunction meds (sildenafil, etc): contraindicated with nitrates







Vitamins or Supplements?

- Overall lower priority than heart failure meds with proven morbidity/mortality benefit
- Concerns:
 - Inconsistent evidence of benefit
 - Drug interactions
 - Pill burden
- Reasonable to treat nutritional deficiencies if provider approves!
- Omega-3 fatty acids reasonable to use
 - Though contributes to pill burden









My Easy

Name: Mark Grace

Date:

Primary Doctor: Dr. Harry Carry

Problems:

Wh

- 1. ACE + ARB
- 2. No beta blocker

3. NSAID in heart failure

Losart

Ibupro

	0 🙂	0 😐	0 😕	
	0 🙂	0 😐):	







Nurse Management Makes a Difference

- Nurse-coordinated management vs. usual care for 706 heart failure patients in Europe
 - 18 month follow-up
 - More patients on target doses of ACE/ARB and beta blockers
 - Improved LVEF
 - Improved NYHA class
 - Improved quality of life (SF-36)





Take Home Points

- ACE/ARB + Beta Blocker per GDMT
- ACE inhibitor dose may be reduced
- Do not start or stop Beta Blockers abruptly
- Torsemide or bumetanide have higher bioavailability than furosemide
- Ask patients about NSAIDs use
- Monitor after any medication changes:
 - Blood pressure, heart rate
 - Serum creatinine, potassium
 - Side effects
- Close follow-up improves outcomes





Please Hold Questions – Thanks!








Break













Disease Progression

Jayne Mitchell, ANP-BC, CHFN OHSU Heart Failure Program





Heart Failure – Stage C

- NYHA class II or III
- Echo shows some type of structural issue and patient has symptoms
- Goals of therapy
 - Patient education
 - Symptom relief
 - Prevent re-hospitalization
 - Prolong survival (medications first, then devices as indicated)
 - Address comorbidities





Current Heart Failure Therapies That Reduce Morbidity and Mortality

DRUGS:

- ACEIs/ARBs
- Beta Blockers
- Aldosterone receptor antagonists
- Hydralazine/nitrates (in AAs)
- Diuretics...probably

DEVICES

- BiV pacemakers
- ICDs
- LVADs

OTHER

Cardiac Transplant







Progression of Disease





Figure 1.

Schematic Depiction of Comprehensive Heart Failure Care Figure illustration by Rob Flewell.













Definitions For Advanced HF

HF Association of European Society of Cardiology

- Severe HF symptoms (NYHA III/IV)
- Episodes of volume overload and/or low resting CO
- Objective evidence of myocardial dysfunction
 - Echo, cath, BNP/NT proBNP
- Poor objective functional capacity
 - Inability to exercise
 - -6 MWT < 300 m
 - Peak V02 < 12 14 cc/kg/min
- More than one HF hospitalization in past 6 months
- Persistence of above despite optimal medical and device therapy

Metra, M et al. EJHF 2007





Advanced Heart Failure

When to Worry

- Recurrent hospitalizations
- CRT nonresponders
- Persistence of third heart sound on exam
- Inability to tolerate ACEs/ARBs and/or beta blockers
- Renal insufficiency is present, e.g. Cardiorenal syndrome
- Poor or worsening functional capacity
- RV dysfunction is present
- High BNP levels
- Recurrent ventricular arrhythmias
- "Diastolic HF" in absence of hypertension

(It won't get better with time)







Heart Failure – Stage D

- NYHA class IIIb or IV for greater than 45 out of 60 days
- Recurrent hospitalizations
- Does not respond to optimal therapy
- **One year mortality may be as high as 30-50%
- Goals of therapy
 - Symptom relief
 - Prevent re-hospitalization
 - Prolong survival- are advance therapies indicated?
 - Improve quality of life as end of life approaches





Case Study – Ms. J Fast Forward


49 year old female comes to office for follow up

- Severe biventricular dysfunction (NICM, LVEF 20%, severe TR, moderate MR)
- History of VT arrest s/p single chamber AICD: Stage D, NYHA IIIb.
- Non-ischemic
 - Significant right sided heart failure with TR
 - Pulmonary HTN
 - RV enlargement and dysfunction.
- S/p single chamber AICD





Case Study – CXR







Case Study – Echo

Height: 66.0 in

Blood Pressure:

122/83 mm/Hg

Weight: 211.0 lb BSA: 2.05 m²

Gender:

Order: 103602447

Sonographer: Tom Mortemore RCS Referring Provider: EMILY MYERS

Patient Location: 5a

Modalities Performed: 2D, Color Doppler, Spectral Doppler and Optison contrast.

Study Quality: This was a technically difficult study, but image quality improved with echo contrast.

Imaging Limitations: Patient size and body habitus. Exam Indication: CHF, Concern for pericardial effusion

Transthoracic Echocardiographic Report

Final Impressions:

- 1. The left ventricular cavity size is severely increased.
- The LV systolic function is severely decreased.
- 3. Visually estimated left ventricular ejection fraction is 20 25%.
- 4. Severely enlarged right ventricle.
- 5. Moderately reduced RV systolic function.
- Moderate mitral valve regurgitation.
- 7. Severe tricuspid regurgitation.
- There is complete lack of coaptation of the tricuspid leaflets due to ventricular and annular enlargement.
- 9. Small pericardial effusion.
- Compared to the most recent exam dated, 10/14/13, there are no significant changes.
- 11. Moderately dilated right atrium.

2D Measurments			
	<u>2D</u>	NL Values	
LVID(d)	6.90 cm	(3.5-5.7cm)	
LVID(s)	6.45 cm		
IVS(d)	0.98 cm	(0.6-1.1cm)	
LVPW(d)	1.45 cm	(0.6-1.1cm)	
Ao(d)	2.80 cm	(2.1-3.5cm)	
LA A/Ps 2D	5.34 cm	(2.7-3.9cm)	
LA area 4c	31.2 cm ²		
LA vol	129.8 ml	(40-73ml)	
LA vol index	$63 \mathrm{ml/m^2}$	(16-28)	
Biplane EF	21.5 %		


2D Magazzaranta

Evaluation of chamber size and geometry is accomplished through






Case Study – Lab








Case Study – Lab







Case Study – Lab







Case Study – Where Is She On The Curve?





Figure 1.

Schematic Depiction of Comprehensive Heart Failure Care Figure illustration by Rob Flewell.













CareOregon Advanced Illness Care (AIC) and Palliative Care

Safety Net Palliative Care

Kelly Hayes, AIC RN CareOregon







Traditional Palliative Care










Safety Net Palliative Care










Traumatic Life Experience










Younger Population

Age Groups









Relationships are the agents of change and the most powerful therapy is human love.

- BRUCE D. PERRY, MD







All Hospice Is Palliative Care, But Not All Palliative Care Is Hospice

Palliative Care	Hospice
Would you be surprised?	Prognosis of 6 months or less
Can continue curative or aggressive treatment	Can NOT continue curative or aggressive treatment
Team: RN, MSW, HHA, Chaplain	Team: Medical Director, RN, MSW, Chaplain, HHA, Volunteer
Can receive skilled care by Home Health	Typically, cannot receive Home Health





Outpatient Palliative Care Available For CareOregon Members

With

- COA Plus or Star
- OHP HSO/CareOregon

Living In

- Clackamas County
- Multnomah County
- Washington County


Suffering From A serious (potentially life-limiting, chronic or progressive) illness and wish to seek curative or life prolonging treatments







Five Programs/Pilots









Palliative Care Considerations

Advanced condition such as advanced cancer or heart, lung, kidney, liver, or cognitive failure with evidence of active decline

- Active decline is defined as any of the following:
 - 2 hospitalizations/or 6 ED visits in the last 12 months
 - Progressive and significant decline in one or more ADLs in the last 3 months
 - Nutritional decline: albumin <3 g/d or 5% weight loss over 6 months





Outpatient palliative care referrals

- Do not require prior authorization, but will be reviewed for appropriateness
- Referral forms are on CareOregon website <u>http://careoregon.org/Res/Documents/Providers/Outpatient_Palliative_Care_Referral_Form.pdf</u>
- Questions about eligibility can be directed to:
 - Julie Ellerman: 503-416-2901 or emailed to ellermanj@careoregon.org





Outpatient Palliative Care Partners

CareOregon ONLY covers palliative care services provided by:

Adventist Health Options – 503-261-6075



- Care Partners 503-648-9565
 - Compass Oncology Only







Additional resources

- Palliative Care: YOU ARE a BRIDGE
 - http://youtu.be/IDHhg76tMHc
- CareOregon Outpatient Palliative Care Policy
 - http://dms/allco/Policies%20%20Procedures/143%20
 Palliative%20Care%20PP.docx
- CareOregon Outpatient Palliative Care Referral Form
 - http://careoregon.org/Res/Documents/Providers/Outp
 atient_Palliative_Care_Referral_Form.pdf





Health Options Outpatient Palliative Care



Laura Macias, RN – CHPN
Clinical Manager OPPC
Adventist Health Homecare Services





Take Home Points

- People are complex
- The story changes- providers, family
- The setting matters- inpatient, clinic, home, appointment
- Listen to what is NOT said, as well as what is said
- Asking questions differently:
 - How are you?
 - How are feeling?







What is Palliative Care?

The National Consensus Project for Quality Palliative Care defined palliative care as the following:

Palliative care means patient and family-centered care that optimizes quality of life by anticipating, preventing, and treating suffering.

Palliative care throughout the continuum of illness involves addressing physical, intellectual, emotional, social, and spiritual needs and to facilitate patient autonomy, access to information, and choice.







Health Options Program Goals

- Increase patient/family understanding of disease process
- Clarify patient-centered goals of care
- Document and communicate healthcare wishes
- Collaborate with healthcare team for timely and appropriate access to care
- Facilitate appropriate transition to hospice and/or alternate level of care







Team Members Interventions Outcomes Education PCP & Clinic about disease **Staff** process Patient/family experience Goals of Care/Advance **Palliative Directives Care RN Planning for Provider Future Events** satisfaction **Palliative** Care MSW **Psycho-social** support Reduction in non-beneficial care Home **Spiritual Health Aide** support





Our Patient – Ms. J

- 51 yo female, living with adult children
- Referred July 2013, admitted November 2013
- Co-morbidities:
 - End Stage Liver Disease
 - Chronic Kidney Disease
 - Intermittent tobacco use
 - Chronic pain
 - Non-adherence to prescribed dietary changes







Health Care Team

OHSU/CareOregon

- PCP
- Cardiology- MD + ANP
- CareOregon Health Resilience Specialist

Home Care Team

- Health Options:
 - RN
 - MSW
 - Home health aid
- Home Health:
 - PT/OT
 - Infusion RN
- Aging and Disabilities
 Services Case Manager





Patient Barriers To Care

- Limited phone accessibility
- Unstable home
- Inconsistent caregiving resources
- Declined home visits during symptomatic episodes
- Patient and family's priorities differed from medical team recommendations
 - Pursue all life-saving interventions
 - Patient not consistent with following recommendations from medical team





Healthcare Team Barriers To Care

- EMRs that do not communicate
- Poor inter-team communication > differing information delivered to patient and family
- Lack of systems for facilitating timely communication on hospital admission







Who is doing what?



AKA – Care Coordination





Health Options RN

- Evaluate patient/family understanding of treatment plan
- Evaluate patient/family goals of treatment- same or different?
- Collaborate with medical team to clarify pt/family understanding and expectations of outcomes of care
- Coordinate with MSW and HHA
- Coordinate communication between inpatient and outpatient Care teams





Health Options MSW

- Evaluate patient/family psychosocial barriers to accessing care and resources
- Coordinate caregiver support
- Advocate for patient-centered goals of care
- Educate patient/family on their role in accessing needed resources
- Provide guidance and support to patient/family:
 - Navigating system to access resources
 - Coping with changes to quality of life/health status
- Coordinate communication between inpatient and outpatient care teams







Ms. J's Story – Months 1 and 2

- First home visits:
 - RN weekly
 - HHA intermittent
 - o MSW
- Caregiving and transportation established
- Admitted to hospital
- Goals of Care Conference
 - Reviewed treatment options
 - Transplant ruled out







Ms. J's Story – Months 3 and 4

- Patient improved with home visits and transportation to clinic visits
- Discharged from home health for meeting goals for <u>strengthening</u> and <u>mobility</u>
- Health Options RN home visits continue
- Patient admitted to PAMC ICU for general weakness with chest and abdominal pain







- In-Hospital Goals of Care Conference with Medical Team,
 PCP, Health Options RN, and multiple family members
 - Patient wants all available life-saving treatments
- Patient transferred to OHSU per her/family request to pursue all available medical treatments
- OHSU Palliative Care Team Consultation:
 - Patient continues to want aggressive treatment only provided in hospital
- Patient discharged from Health Options
- Health Options staff remained in contact with OHSU care team to discuss hospital discharge plans





- Ethics Consult and Goals of Care discussion
 - Unable to go to SNF w/ dobutamine infusion
 - Patient able to discharge home with dobutamine infusion; family members providing caregiving
- Health Options MSW onboard to coordinate care and support patient's goals of care
- Health Options RN coordinated with Home Infusion service and PCP for ongoing symptom management







- Ms. J expressed desire to die at home, but declined further planning or discussion
- Family members not in agreement with Ms. J's stated wishes
- Joint visits done by Health Options RN and MSW
 - Assisted patient & family with goal planning
 - Completed Advanced Directives/POLST
 - Patient remained Full Code at end of discussion







Ms. J's Story – Months 8 and 9

- Breakdown in caregiving → admitted with fluid overload after ICD fired
- Upon discharge, Ms. J remained full code, but stated her intention to stay out of the hospital
- Continued concerns around in-home caregiving
 - Noted deterioration in Ms. J's physical appearance during clinic appointments
 - Ms. J reporting more anxiety, fear of dying to provider
- Ms. J
 - Made effort to stop smoking-started using nicotine patch
 - Not tracking weight or fluid/sodium intake
 - Not willing to move to higher level of care or change code status
 - Taking several day trips, not available for home visits





- Admitted to Legacy Mt. Hood after driving → revealed caregiving breakdown with patient spending many hours home alone
- Patient declined to move to higher level of care

Health Options MSW working with PCP to get Life Alert

in home







- Ms. J reporting issues w/ nausea/vomiting, not well managed
- Ms. J progressively gaining weight with increasing abd girth and increasing shortness of breath
- Complete breakdown of in-home caregiving
- Ms. J struggling to self-manage all details of her care needs

While the above is going on:

- Ms. J expresses different wishes with health care team and family
 - Health care team → transition to hospice
 - Family → remain full code





- Multiple hospital and ICU admissions
 - Patient remains full code
 - Must discharge home with caregiving
- Care Conferences with medical team and family
 - Family observe some signs that give them hope for patient to improve
 - Patient remains Full Code, remains in-hospital due to acuity of interventions and refusal to transition to Hospice





Ms. J's Story – Month 12 Cont.

- Health Options RN and MSW communicated regularly with in-patient care team as patient continued to decline and refused transition to hospice care
- Patient coded, intubated and taken to ICU
- Care Conference with patient's sons, who agreed to withdrawal of life support, resulting in patient death







Ms. J's Care

- In the 12 months that MBJ was connected with Health Options:
 - 6 case conferences
 - 2 team meetings
 - 1 Ethics Consultation
 - 180 touches by OPPC team
- Ms. J was able to be home from May-Oct as Health Options was able to help coordinate services and care needed for dobutamine infusion
- Ms. J received patient-centered care with interventions driven by her desired Goals of Care





How Did Health Options Impact Care?

- Clarification of home situation and resources available
- Understanding of how home situation was impacting her immediate health status and decision making
- Continued education and clarification of expectations with patient and family, while coordinating with primary medical team
- Streamlining and clarifying inter-team communication
- While the final outcome was not "ideal" from perspective of medical team, it was in line with patient's stated wishes for care







Take Home Points

- Family dynamics
- Not linear
- "It's messy"
- Takes a village not just one provider





Questions?







Thank you!



